NCT07612657Not yet recruitingPhase 3
A Randomized, Double-blind, Placebo-controlled, Safety and Efficacy Study of VI-0106 (Extended-release Tacrolimus) in Subjects With PAH and Functional Limitations Despite Optimized Treatment With Available PAH Medications
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Not yet recruiting
- Sponsor
- VIVUS LLC
- Enrollment
- 300
Study Overview
Brief Summary
This study evaluates the effects of VI-0106 (an extended-release formulation of tacrolimus) in participants with pulmonary arterial hypertension (PAH) who continue to have functional limitations despite being on optimized background PAH therapy. Participants will be randomly assigned with equal chance to receive either VI-0106 or placebo in a double-blind fashion to assess whether VI-0106 improves outcomes in this population.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Care Provider, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •WHO Group 1 PH: Pulmonary Arterial Hypertension;
- •WHO functional class II - IV despite optimized treatment with one or more modalities. Treatments for PAH must be stable for at least 3 months at the time of screening;
- •Right heart catheterization (RHC) at screening (or within 3 months prior to screening);
- •Screening 6MWD >75 meters to ≤450 meters.
Exclusion Criteria
- •PAH due to pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis
- •Chronic thromboembolic or portopulmonary hypertension
- •Total Lung Capacity (TLC) <60% predicted;
- •FEV1/FVC <70% predicted or FEV1 <60% predicted;
- •Evidence of left-sided heart disease;
- •Inability to safely attempt completion of the 6MWD;
- •Life expectancy <6 months;
- •eGFR <30 mL/min/1.73 m2 (CKD-EPI equation);
- •Moderate to severe hepatic dysfunction (Child-Pugh score >10);
- •Serum potassium >5.1 mEq/L;
- •Use of experimental PAH treatments within the past 3 months;
- •Active infection requiring antibiotic, antifungal, or antiviral therapies;
- •Current systemic treatment with cyclosporine;
- •Known allergy or hypersensitivity to tacrolimus;
- •Significant psychiatric, addictive, or other disorder that compromises the subject's ability to provide informed consent, follow study protocol, or adhere to study treatment
Investigators
Similar Trials
Recruiting
Phase 2
VEL-101 to Prevent Rejection After Kidney TransplantationNCT07290777Veloxis Pharmaceuticals120
Recruiting
Phase 2
A Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults with Celiac DiseaseCeliac Disease2024-517081-42-00Teva Branded Pharmaceutical Products R&D LLC5
Completed
Phase 1
PA-001 Ph.1 Study in Healthy and Elderly SubjectsCOVID - 19NCT07518771PeptiDream Inc.47
Not yet recruiting
Phase 3 4
Effect of Vaitrain Basti and Anuvasana Basti With Ashtkatwar Taila in the Management Of SciaticaCTRI/2024/09/074159Dr Sarvapalli Radhakrishnan Rajasthan Ayurved University Kadwar Jodhpur Rajasthan60
Recruiting
Phase 1
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of SIM0811 Injection in Healthy Chinese Adult ParticipantsNCT07345364Jiangsu Simcere Pharmaceutical Co., Ltd.72